Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.580
-0.040 (-0.87%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 2.80M AUD in the half year ending December 31, 2025, with 47.49% growth. This brings the company's revenue in the last twelve months to 8.84M, up 137.32% year-over-year. In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 7.64M with 90.12% growth.
Revenue (ttm)
8.84M AUD
Revenue Growth
+137.32%
P/S Ratio
17.66
Revenue / Employee
982,113 AUD
Employees
9
Market Cap
78.18M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.64M | 3.62M | 90.12% |
| Jun 30, 2024 | 4.02M | 102.96K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 638.30K | 14.23% |
| Jun 30, 2021 | 4.49M | 4.36M | 3,554.58% |
| Jun 30, 2020 | 122.73K | -4.83M | -97.52% |
| Jun 30, 2019 | 4.95M | 1.83M | 58.40% |
| Jun 30, 2018 | 3.13M | 103.11K | 3.41% |
| Jun 30, 2017 | 3.02M | -1.87M | -38.27% |
| Jun 30, 2016 | 4.90M | -1.60M | -24.61% |
| Jun 30, 2015 | 6.49M | -1.71M | -20.89% |
| Jun 30, 2014 | 8.21M | 3.57M | 76.95% |
| Jun 30, 2013 | 4.64M | 2.11M | 83.56% |
| Jun 30, 2012 | 2.53M | 2.36M | 1,451.39% |
| Jun 30, 2011 | 162.92K | -52.09K | -24.23% |
| Jun 30, 2010 | 215.01K | -213.19K | -49.79% |
| Jun 30, 2009 | 428.19K | -62.92K | -12.81% |
| Jun 30, 2008 | 491.11K | -16.32K | -3.22% |
| Jun 30, 2007 | 507.44K | -542.85K | -51.69% |
| Jun 30, 2006 | 1.05M | -1.60M | -60.41% |
| Jun 30, 2005 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 57.95M |
| Q32 Bio | 53.74M |
| Gossamer Bio | 48.47M |
| Sangamo Therapeutics | 39.55M |
| NeurAxis | 3.57M |
| eXoZymes | -700.00 |
ATHE News
- 1 day ago - Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development - GuruFocus
- 1 day ago - Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study - Nasdaq
- 1 day ago - Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy - GlobeNewsWire
- 6 days ago - Alterity Therapeutics (ATHE) Shows Promising Results in Phase 2 Trial for MSA - GuruFocus
- 6 days ago - Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology - GlobeNewsWire
- 11 days ago - Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics (ATHE) Prepares for Phase 3 Trial After FDA Feedback - GuruFocus
- 4 weeks ago - Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program - GlobeNewsWire